Selected research
Industry Research
Montelukast API Industry Research Report 2026
Market perspective
The global Montelukast API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Montelukast API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Montelukast API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Montelukast API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Montelukast API include Merck, Mylan, Teva Pharmaceutical Industries, Sun Pharma, Sanyo Chemical Industries, Morepen Laboratories, Intas Pharmaceuticals, Delmar Chemicals and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Montelukast API market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Montelukast API Market by Company
Merck
Mylan
Teva Pharmaceutical Industries
Sun Pharma
Sanyo Chemical Industries
Morepen Laboratories
Intas Pharmaceuticals
Delmar Chemicals
Cipla
Apotex
Montelukast API Segment by Type
Chewable Tablet
Oral Solution
Tablet
Montelukast API Segment by Application
Bronchospasm
Urticaria
Asthma
Allergic Rhinitis
Others
Montelukast API Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Montelukast API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Montelukast API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Montelukast API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Montelukast API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chewable Tablet
- Oral Solution
- Tablet
Applications
- Bronchospasm
- Urticaria
- Asthma
- Allergic Rhinitis
- Others
Companies covered
- Merck
- Mylan
- Teva Pharmaceutical Industries
- Sun Pharma
- Sanyo Chemical Industries
- Morepen Laboratories
- Intas Pharmaceuticals
- Delmar Chemicals
- Cipla
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Montelukast API Market Size (2021-2032)
- 2.2.2 Global Montelukast API Sales (2021-2032)
- 2.2.3 Global Montelukast API Market Average Price (2021-2032)
- 2.3 Montelukast API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Chewable Tablet
- 2.3.3 Oral Solution
- 2.3.4 Tablet
- 2.4 Montelukast API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bronchospasm
- 2.4.3 Urticaria
- 2.4.4 Asthma
- 2.4.5 Allergic Rhinitis
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Montelukast API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Montelukast API Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Montelukast API Revenue of Manufacturers (2021-2026)
- 3.4 Global Montelukast API Average Price by Manufacturers (2021-2026)
- 3.5 Global Montelukast API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Montelukast API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Montelukast API, Product Type & Application
- 3.8 Global Manufacturers of Montelukast API, Established Date
- 3.9 Global Montelukast API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Montelukast API Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Montelukast API Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Teva Pharmaceutical Industries
- 4.3.1 Teva Pharmaceutical Industries Company Information
- 4.3.2 Teva Pharmaceutical Industries Business Overview
- 4.3.3 Teva Pharmaceutical Industries Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Pharmaceutical Industries Montelukast API Product Portfolio
- 4.3.5 Teva Pharmaceutical Industries Recent Developments
- 4.4 Sun Pharma
- 4.4.1 Sun Pharma Company Information
- 4.4.2 Sun Pharma Business Overview
- 4.4.3 Sun Pharma Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharma Montelukast API Product Portfolio
- 4.4.5 Sun Pharma Recent Developments
- 4.5 Sanyo Chemical Industries
- 4.5.1 Sanyo Chemical Industries Company Information
- 4.5.2 Sanyo Chemical Industries Business Overview
- 4.5.3 Sanyo Chemical Industries Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanyo Chemical Industries Montelukast API Product Portfolio
- 4.5.5 Sanyo Chemical Industries Recent Developments
- 4.6 Morepen Laboratories
- 4.6.1 Morepen Laboratories Company Information
- 4.6.2 Morepen Laboratories Business Overview
- 4.6.3 Morepen Laboratories Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Morepen Laboratories Montelukast API Product Portfolio
- 4.6.5 Morepen Laboratories Recent Developments
- 4.7 Intas Pharmaceuticals
- 4.7.1 Intas Pharmaceuticals Company Information
- 4.7.2 Intas Pharmaceuticals Business Overview
- 4.7.3 Intas Pharmaceuticals Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Intas Pharmaceuticals Montelukast API Product Portfolio
- 4.7.5 Intas Pharmaceuticals Recent Developments
- 4.8 Delmar Chemicals
- 4.8.1 Delmar Chemicals Company Information
- 4.8.2 Delmar Chemicals Business Overview
- 4.8.3 Delmar Chemicals Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Delmar Chemicals Montelukast API Product Portfolio
- 4.8.5 Delmar Chemicals Recent Developments
- 4.9 Cipla
- 4.9.1 Cipla Company Information
- 4.9.2 Cipla Business Overview
- 4.9.3 Cipla Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cipla Montelukast API Product Portfolio
- 4.9.5 Cipla Recent Developments
- 4.10 Apotex
- 4.10.1 Apotex Company Information
- 4.10.2 Apotex Business Overview
- 4.10.3 Apotex Montelukast API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Apotex Montelukast API Product Portfolio
- 4.10.5 Apotex Recent Developments
5 Global Montelukast API Market Scenario by Region
- 5.1 Global Montelukast API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Montelukast API Sales by Region: 2021-2032
- 5.2.1 Global Montelukast API Sales by Region: 2021-2026
- 5.2.2 Global Montelukast API Sales by Region: 2027-2032
- 5.3 Global Montelukast API Revenue by Region: 2021-2032
- 5.3.1 Global Montelukast API Revenue by Region: 2021-2026
- 5.3.2 Global Montelukast API Revenue by Region: 2027-2032
- 5.4 North America Montelukast API Market Facts & Figures by Country
- 5.4.1 North America Montelukast API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Montelukast API Sales by Country (2021-2032)
- 5.4.3 North America Montelukast API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Montelukast API Market Facts & Figures by Country
- 5.5.1 Europe Montelukast API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Montelukast API Sales by Country (2021-2032)
- 5.5.3 Europe Montelukast API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Montelukast API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Montelukast API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Montelukast API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Montelukast API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Montelukast API Market Facts & Figures by Country
- 5.7.1 South America Montelukast API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Montelukast API Sales by Country (2021-2032)
- 5.7.3 South America Montelukast API Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Montelukast API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Montelukast API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Montelukast API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Montelukast API Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Montelukast API Sales by Type (2021-2032)
- 6.1.1 Global Montelukast API Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Montelukast API Sales Market Share by Type (2021-2032)
- 6.2 Global Montelukast API Revenue by Type (2021-2032)
- 6.2.1 Global Montelukast API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Montelukast API Revenue Market Share by Type (2021-2032)
- 6.3 Global Montelukast API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Montelukast API Sales by Application (2021-2032)
- 7.1.1 Global Montelukast API Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Montelukast API Sales Market Share by Application (2021-2032)
- 7.2 Global Montelukast API Revenue by Application (2021-2032)
- 7.2.1 Global Montelukast API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Montelukast API Revenue Market Share by Application (2021-2032)
- 7.3 Global Montelukast API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Montelukast API Value Chain Analysis
- 8.1.1 Montelukast API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Montelukast API Production Mode & Process
- 8.2 Montelukast API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Montelukast API Distributors
- 8.2.3 Montelukast API Customers
9 Global Montelukast API Analyzing Market Dynamics
- 9.1 Montelukast API Industry Trends
- 9.2 Montelukast API Industry Drivers
- 9.3 Montelukast API Industry Opportunities and Challenges
- 9.4 Montelukast API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst